Active Ingredient History

  • Now
Orvepitant (GW823296) is a drug developed by GlaxoSmithKline which acts as a selective antagonist for the NK1 receptor. It was under development as a potential antidepressant drug, and early stage human clinical trials showed it to have some antidepressant effects, though not with sufficient efficacy to justify further development for this application. It was however considered a successful proof of concept for NK1 antagonists as potential antidepressants, and efforts are continuing to find more potent compounds which might be more effective.   Wikipedia

  • SMILES: C[C@@H](N(C)C(=O)N1CC[C@@H](C[C@@H]1c2ccc(F)cc2C)N3CCN4[C@@H](CCC4=O)C3)c5cc(cc(c5)C(F)(F)F)C(F)(F)F
  • Mol. Mass: 628.63
  • ALogP: 6.8
  • ChEMBL Molecule:
More Chemistry
gw823296 | gw823296x | orvepitant | orvepitant maleate


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue